Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | IPH5201 |
| Trade Name | |
| Synonyms | IPH-5201|IPH 5201|IPH52 |
| Drug Descriptions |
IPH5201 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound CD39, resulting in decreased ATP hydrolysis, which potentially leads to activation of T-lymphocytes and anti-tumor immune response (PMID: 31116985, PMID: 31244820). |
| DrugClasses | Adenosine Targeting 24 CD39 Antibody 5 |
| CAS Registry Number | NA |
| NCIT ID | C175591 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Durvalumab + IPH5201 + Paclitaxel | Carboplatin Durvalumab IPH5201 Paclitaxel | 0 | 1 |
| Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium | Carboplatin Durvalumab IPH5201 Pemetrexed Disodium | 0 | 1 |
| Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium | Cisplatin Durvalumab IPH5201 Pemetrexed Disodium | 0 | 1 |
| Durvalumab + IPH5201 | Durvalumab IPH5201 | 0 | 1 |
| Durvalumab + IPH5201 + Oleclumab | Durvalumab IPH5201 Oleclumab | 0 | 1 |
| IPH5201 | IPH5201 | 0 | 1 |